Management of acute and early HIV-1 infection

AIDS Reviews

Volumn 2, Issue 3, 2000, Pages 136-143

  Little, S J ^a   Perrin, L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute HIV; Antiretroviral therapy; Primary HIV; Resistance; Seroconversion

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS VACCINE; ZIDOVUDINE;

ACUTE DISEASE; CLINICAL TRIAL; DISEASE CARRIER; DISEASE RESISTANCE; DRUG POTENCY; FACTORIAL ANALYSIS; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LONG TERM CARE; MEDICAL CARE; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PATIENT EDUCATION; PHENOTYPE; REVIEW; SCHOOL CHILD; SCREENING; SEROCONVERSION; TOXICITY TESTING; VIRUS GENE; VIRUS TRANSMISSION;

EID: 0034547869     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion
2. Primary human T-lymphotropic virus type III infection
3. Characterization of the acute clinical illness associated with human immunodeficiency virus infection
4. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection
5. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection
6. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
7. Clinical and epidemiologic features of primary HIV infection
8. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group
9. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection
10. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: Is the diagnosis too restrictive?
11. Symptomatic primary infection due to human immunodeficiency virus type 1: Review of 31 cases
12. Prognostic value of serum HIV-RNA levels of virologic steady state after seroconversion: Relation to CD4 cell count and clinical course of primary infection
13. Viral dynamics of acute HiV-I infection
14. Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney
15. Awkward moments in patient-physician communication about HIV risk
16. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection
17. Biological and virologic characteristics of primary HIV infection
18. Severity and prognosis of acute human immunodeficiency virus type 1 illness: A dose-response relationship
19. Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocytes in the first year of HIV-1 infection
20. Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS
21. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure
22. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors
23. Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel
24. Screening for primary human immunodeficiency virus type 1 infection
25. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study
26. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
27. Zidovudine in the management of primary HIV-1 infection
28. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection implications for timing of antiretroviral therapy
29. HIV-1 infection despite immediate combination antiviral therapy after infusion of contaminated white cells
30. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
31. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
32. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
33. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy
34. Longitudinal HIV-1 RNA levels in a cohort of homosexual men
35. Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study correlates and temporal trends of virus load
36. Course of viral load throughout HIV-1 infection
37. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study
38. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
39. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study
40. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: A predictor of long-term mortality in HIV infection
41. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users plasma viral load and CD4+ cell count
42. Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes
43. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
44. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
45. Antiviral pressure exerted by HIV-1 specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
46. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
47. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
48. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
49. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
50. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
51. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
52. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
53. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
54. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
55. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
56. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
57. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
58. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression
59. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS)
60. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)
61. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
62. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study
63. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
64. Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection
65. Non-cytologic CD8 T-cell anti-HIV responses in primary HIV-1 infection
66. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients
67. HIV-specific cellular and humoral immune responses in primary HIV infection
68. Reduction of HIV concentration during acute infection: Independence from a specific immune response
69. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
70. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor
71. The impact of the synctium-inducing phenotype of human immunodeficiency virus on disease progression
72. A controlled trial of zidovudine in primary human immunodeficiency virus infection
73. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: A randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative
74. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
75. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
76. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia
77. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor
78. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection
79. Combined therapy with zidovudine and L-697,661 in primary HIV infection
80. Zidovudine plus didanosine in primary HIV-1 infection
81. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia. The Swiss HIV Cohort Study
82. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
83. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection
84. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
85. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
86. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
87. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue
88. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
89. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group
90. Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
91. Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel
92. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
93. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
94. HIV-1 drug resistance in newly infected individuals
95. Reduced susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from patients with primary HIV infection to nonnucleaoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites
96. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naïve patients (study DMP 266-006)
97. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiviral therapy
98. Selective vertical transmission of HIV-1 antiretroviral resistance mutations
99. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1
100. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS - Characteristics and natural history of the virus
101. The spectrum and frequency of reduced antiretroviral drug susceptibility with primary HIV infection in North America
102. Peak in the transmission of drug-resistant variants in 1997 is followed by a reflux in Switzerland
103. Reduced antiretroviral drug susceptibility among patients with primary HIV infection